# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

# **CURRENT REPORT**

## Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 15, 2016 Date of Report (Date of earliest event reported)

# Flex Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

of incorporation)

001-36812

(Commission File Number)

46-5087339 (IRS Employer Identification No.)

800 Boylston Street, 24th Floor Boston, MA

(Address of principal executive offices)

Registrant's telephone number, including area code: (617) 874-1821

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

02199

(Zip Code)

## Item 7.01. Regulation FD Disclosure.

On November 15, 2016, Flex Pharma, Inc. will present a poster entitled "Chemical Neuro Stimulation of TRPV1 and TRPA1 Sensory Neurons Decreases Muscle Cramps in Humans" at the Society for Neuroscience Conference. The poster is furnished herewith as Exhibit 99.1.

The information contained in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 7.01 shall be deemed to be furnished and not filed:

Exhibit No.

Description

99.1 Flex Pharma, Inc. Poster

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# Flex Pharma, Inc.

Dated: November 15, 2016

By: /s/ Robert Hadfield

Robert Hadfield General Counsel and Secretary

# INDEX TO EXHIBITS

Exhibit No.


99.1 Flex Pharma, Inc. Poster

Description

#### **FLEXPharma** Chemical Neuro Stimulation of TRPV1 and TRPA1 Sensory **Neurons Decreases Muscle Cramps in Humans** Novel Treatments for Neuromuscular Conditions Glenn F. Short III, Laura B. Rosen, Robin Sutherland, Jian Liu, Jennifer M. Cermak, Gary Maier and Thomas Wessel Figure 6. FLX-787 is not systemically available in its parent form in humans Summary Methods Figure 8. Interim data analyses of NLC Exploratory POC Studies signal efficacy and carry-over effects Chemical Neuro Struniation is the treatment of neurological disorders by using small molecules applied topically to sensor howards the the behavior of distinct neural incut within the central nervous system. We have devised one such approach whereby the co-activation of TRPU and TRPU in distribution of the sensor of the se Total FLX-787 (parent + conjugate) Parent FLX-787 by EMG to m . Millīrama intensity an cramp curv cramp inte treatment I products or compared to referred to of duration were measures $v_{\mu\nu} = \psi(k)$ and $v_{\mu\nu} = \psi(k)$ , which is a similar as a subject-specific baseline control. After consumption of First Phrases v which control, the resulting DMGs were quantified for ramp AUC and duration and so baseline values. The time at which the subject received treatment or vehicle control is placererideer 20920au ntaining 19 mg FLX-787 ma only conjugates (LLOQ 0.100 1h after The pare ng/mL). Suggests parent d er PO administration of a liquid for arent form of FLX-787 was not deb -Study 1: Eff and


### **Topical Chemical Neuro Stimulation**

Presentation Number: 537.15




Results

# Figure 4. Topical exposure to oropharynx and esophagus is required for cramp inhibition 2000 2000 2000 2000 2000 2000 ŢŢŢŢ Ť \_\_\_\_\_ Treatment nat activates both TR (29 mg), a single molecule that activates both TBPR, a greater decrease in crame intensity compared to oth The effect of treatment was calculated based upon the pre-treatment baseline crame. Tkx737 treatment is in in AUC compared to its study specific while control emonstrated a significant difference from study-spa are annotated with an asteriak (\* pr0.05, \*\* p < 0.01).



p<0.05) Efficacy saturates at 32 mg FLX-787-ODT



of 0.100 ng/mL; Total FLX-787 Bioanal method The van and ext re semi-quantitative with LLOQ of <0.200 ng/mL ility noted in the metabolic conversion of FLX-787 to conjugates suggests rapid ive phase 2 metabolism (first pass likely at the enterocycle level)

### NLC Exploratory POC Studies

#### \* Nocturnal leg cramps (NLC)

- 50% of those over the age of 50 suffer from NLC with increasing prevalence and frequency with age; Cver 4 million in the US over age 65 suffer daily. Lack of clinical evidence that common "remedies" such as electrolyte replacement, hannas and hydration afford relief. Quinine, prescribed in the United Kingdom for MLC; is associated with and is no longer approved in the US for MLC. No approved drug alternative in US to treat NLC.

#### References

Mineta MA, Holdan A, Botter A, and Farina D. Exerc. Sport Sci. Rev. 41(1):3-40, 2019. Mineta V. Elektronyco Clin Honeyshysiol. 32 (2):730, 1984. Oliun, M. & Lampi, I. Marer Manazari, 11: 525–537, 2008. Benefinito et al., ANN Physiol Classification VeryPeol 2510, Clin Chin. 538, 2009. Vi et al., And J Physiol Classification Liner Physiol 2510, Clin Chin. 530, 2009. Di Star & E. et al. Chinana Databased Of Sciences Network Hang, 2009.

Center Trials in NLC: Two randomized, double-blind, placebo-controlled, cross-over studies to te the effects of a FLX-787 on the frequency of nocturnal leg foot/cramps when self-administered imately 45 minutes before going to bed. ncy, p+0.06) with ODT in sub-(n=37) of p Dida from 1 site (in-so) exclusion
 Study 2 (dosing/formulation): Significant effect (cramp frequency, p<0.05) in first expo analysis (repeated, sequentia), multiple crossovers, n=29 from prior NLC study)
 Statistically significant on some, but not all crossover endpoints sure paralle 
 Figure 9. Effect sizes calculated for the parallel portion of the cross-over studies are on-average larger than those reported in the quinine clinical literature

 Endpoint
 Treatment/Study
 Nine
 Name
 Effect

 TRP-56m
 50
 50
 50
 50

 Frequency
 FLX-387(00T)\$50:091\*
 72
 37
 0.06
 0.77

 FLX-387(00[U55tody1\*
 72
 29
 29
 0.02
 0.94

- \*The effect size of Study 1 is a sub-analysis (n=37) excluding data from 1 site (n=35). oratory ANOVA analyses across studies showed a period effect within each cross-over oid the potential influence of carry-over on effect size estimates were calculated from the first
- Exploratory AMOVA analyses across studies showed a period effect within each cross-over
   To avoid the potential influence of carry-over on effect size estimates were calculated from the first
  exposure in each study
   Average effect size of cramp frequency derived from quinine literature is 0.12 (95%Cl-3.5,-1.36)). (6)

### Conclusions

- FLX-787 has demonstrated a sigmoidal dose-response curve in a human EIC-model in the absence of systemic exposure.
   Topical Chemical Neuro Stimulation of TRPA1/TRPV1 indirectly inhibits
- α-motor neuron hyperexcitability.
- ac-motor neuron hyperexcitability. FUX-787 has shown positive signals on cramp frequency in the parallel design portion of two exploratory human POC NLC studies. FUX-787 is well tolerated and safe, and no SAEs have been reported. Consistent with FDA guidance, future FLX-787 studies in NLC will be parallel design with emphasis on patient selection, data capture & monitorine &
- monitoring. Clinical studies in MS and ALS are underway to explore the utility of FLX-787 in additional indications of different etiology where cramping
- and/or spasticity is prevalent. Planned initiation of IND-opening Phase 2 parallel design study in H1 2017.

